RxDoctor Payments Data

Pamela Warnick, MD

Infectious Disease · Chicago, ILNPI 1013920156

Payments from drug & device makers

$4,541in general payments, 2019–2025

Across 16 payments — averaging $283.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$4K
  • Pfizer$44
  • Johnson & Johnson$28
  • Viiv Healthcare Company$20
  • Novo Nordisk$19
  • GSK$18
  • plus $16 from 1 others

What the payments were for

  • Consulting fees$3,14069%
  • Travel & lodging$1,14025%
  • Food & beverage$2335%
  • Education$281%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,541 in reported general payments places this provider in the 80th percentile of 368 infectious disease providers in Illinois.

See all infectious disease providers in Illinois

Medicare billing

Part B allowed, 2024
$22,400
Medicare patients
55
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala440$1,999,253
DovatoDolutegravir Sodium/Lamivudine93$301,418
TivicayDolutegravir Sodium114$278,549
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf49$274,459
JulucaDolutegravir/Rilpivirine64$248,753
OdefseyEmtricitab/Rilpiviri/Tenof Ala48$189,200
DescovyEmtricitabine/Tenofov Alafenam56$140,504
GenvoyaElviteg/Cob/Emtri/Tenof Alafen31$128,530
TriumeqAbacavir/Dolutegravir/Lamivudi25$100,775
IsentressRaltegravir Potassium25$83,272
VemlidyTenofovir Alafenamide52$79,441
Darunavir63$76,758
PifeltroDoravirine34$64,738
PrezcobixDarunavir/Cobicistat18$47,619
Etravirine29$40,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya, Vemlidy$4,396$2,347,728579 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq$20$929,495296 claims
Johnson & JohnsonPrezcobix$28$47,61918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 368 infectious disease providers in Illinois.

Other infectious disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →